Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - OtherShares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Chemomab Therapeutics (CMMB) Receivables - Net (2017 - 2019)

Chemomab Therapeutics posted quarterly Receivables - Net of $408000.0 for Q4 2019, down 88.01% year-on-year from $3.4 million in Q4 2018, and down 66.99% on a QoQ basis from $1.2 million in Q3 2019.

Chemomab Therapeutics (CMMB) has 3 years of Receivables - Net data on file, last reported at $408000.0 in Q4 2019.

  • For the quarter ending Q4 2019, Receivables - Net fell 88.01% year-over-year to $408000.0; the trailing twelve-month figure through Dec 2019 stood at $408000.0 (down 88.01% YoY), and the FY2019 full-year result was $408000.0, down 88.01% from the prior year.
  • Receivables - Net for Q4 2019 stood at $408000.0, down from $1.2 million in the prior quarter.
  • Across five years, Receivables - Net topped out at $3.4 million in Q4 2018 and bottomed at $400000.0 in Q4 2017.
  • The 3-year median for Receivables - Net is $885000.0 (2019), against an average of $1.3 million.
  • The widest annual swing landed in 2018, when Receivables - Net jumped 750.75%; it then tumbled 88.01% in 2019.
  • A 3-year view of Receivables - Net shows it stood at $400000.0 in 2017, then surged by 750.75% to $3.4 million in 2018, then sank by 88.01% to $408000.0 in 2019.
  • The last three Receivables - Net figures came in at $408000.0 (Q4 2019), $1.2 million (Q3 2019), and $885000.0 (Q2 2019), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Chemomab Therapeutics 959.23 Mn 948.86 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2019 408,000.00
Dec 31, 2019 408,000.00
Sep 30, 2019 1.24 Mn
Sep 30, 2019 1.24 Mn
Jun 30, 2019 885,000.00
Jun 30, 2019 885,000.00
Dec 31, 2018 3.40 Mn
Dec 31, 2018 3.40 Mn
Dec 31, 2017 400,000.00
Dec 31, 2017 400,000.00